Effects of metformin on gonadotropin-induced ovulation in women with polycystic ovary syndrome

Fertility and Sterility

Volumn 72, Issue 2, 1999, Pages 282-285

  De Leo, Vincenzo ^a   Marca, Antonio La ^a   Ditto, Antonino ^a,b   Morgante, Giuseppe ^a,b   Cianci, Antonio ^a,b  

^a UNIVERSITY OF SIENA   (Italy)

^b UNIVERSITY OF CATANIA   (Italy)

Author keywords

FSH; Metformin; Ovulation induction; PCOS

Indexed keywords

CHORIONIC GONADOTROPIN; CLOMIFENE CITRATE; ESTRADIOL; METFORAL; METFORMIN; PROGESTERONE; UNCLASSIFIED DRUG; UROFOLLITROPIN;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HORMONAL THERAPY; HORMONE BLOOD LEVEL; HUMAN; HYPERINSULINISM; INTRAMUSCULAR DRUG ADMINISTRATION; OVARY FOLLICLE MATURATION; OVARY POLYCYSTIC DISEASE; OVULATION INDUCTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

ADULT; ANDROSTENEDIONE; CLOMIPHENE; DRUG THERAPY, COMBINATION; ESTRADIOL; FEMALE; FERTILITY AGENTS, FEMALE; FOLLICLE STIMULATING HORMONE; HUMANS; HYPOGLYCEMIC AGENTS; LUTEINIZING HORMONE; METFORMIN; OVULATION; POLYCYSTIC OVARY SYNDROME; PREGNANCY; PROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 0033179753     PISSN: 00150282     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0015-0282(99)00208-3     Document Type: Article

References (21)

1. Franks S. Polycystic ovary syndrome. N Engl J Med. 333:1995;853-861.
2. Tulandi T., Mcinnes R.A., Arronet G.H. Ovarian hyperstimulation syndrome following ovulation induction with HMG. Int J Fertil. 29:1984;113-119.
3. Dunaif A. Insulin resistance and the polycystic ovary syndrome mechanism and implications for pathogenesis. Endocr Rev. 18:1997;774-800.
4. Nestler J.E., Jakubowicz D.J. Lean women with polycystic ovary syndrome respond to insulin reduction with decreases in ovarian P450c17α activity and serum androgens. J Clin Endocrinol Metab. 82:1997;4075-4079.
5. Nestler J.E., Jakubowicz D.J., Evans W.S., Pasquali R. Effects of metformin on spontaneous and clomiphene-induced ovulation in the polycystic ovary syndrome. N Engl J Med. 338:1998;1876-1880.
6. Bailey C.J., Turner R.C. Metformin drug therapy. N Engl J Med. 334:1996;574-579.
7. Bailey C.J. Biguanides and NIDDM. Diabetes Care. 15:1992;755-772.
8. Diamanti-Kandarakis E., Kouli C., Tsianateli T., Bergiele A. Therapeutic effects of metformin on insulin resistance and hyperandrogenism in polycystic ovary syndrome. Eur J Endocrinol. 138:1998;269-274.
9. Burghen G.A., Givens J.R., Kitabachi A.E. Correlation of hyperandrogenism with hyperinsulinism in polycystic ovarian disease. J Clin Endocrinol Metab. 50:1980;113-116.
10. Dunaif A. Insulin resistance and ovarian hyperandrogenism. Endocrinologist. 2:1992;248-260.
11. Nestler J.E., Powers L.P., Matt D.W., Steingold K.A., Plymate S.R., Rittmaster R.S., et al. A direct effect of hyperinsulinemia on serum sex-hormone binding globulin levels in obese women with the polycystic ovary syndrome. J Clin Endocrinol Metab. 72:1991;83-89.
12. Leroith D., Werner H., Beitner-Johnson D., Roberts C.T. Jr. Molecular and cellular aspects of the insulin-like growth factor I receptor. Endocr Rev. 16:1995;143-163.
13. Poretsky L., Glover B., Laumas V., Kalin M., Dunaif A. The effects of experimental hyperinsulinemia on steroid secretion, ovarian insulin receptors, and ovarian type I insulin-like-growth-factor receptors in the rat. Endocrinology. 122:1988;581-585.
14. Froesch E.R., Zapf J. Insulin-like growth factors and insulin comparative aspects. Diabetologia. 28:1985;485-493.
15. Willis D., Franks S. Insulin action in human granulosa cells from normal and polycystic ovaries is mediated by the insulin receptor and not the type-I insulin-like growth factor receptor. J Clin Endocrinol Metab. 80:1995;3788-3790.
16. Fulghesu A.M., Villa P., Pavone V., Guido M., Apa R., Caruso A., et al. The impact of insulin secretion on the ovarian response to exogenous gonadotropins in polycystic ovary syndrome. J Clin Endocrinol Metab. 82:1997;644-648.
17. Velazquez E., Acosta A., Mendoza S.G. Menstrual cyclicity after metformin therapy in polycystic ovary syndrome. Obstet Gynecol. 90:1997;392-395.
18. Velazquez E.M., Mendoza S., Hamer T., Sosa F., Gluek C.J. Metformin therapy in polycystic ovary syndrome reduces hyperinsulinemia, insulin resistance, hyperandrogenemia, and systolic blood pressure, while facilitating normal menses and pregnancy. Metabolism. 43:1994;647-654.
19. Acbay O., Gundogdu S. Can metformin reduce insuline resistance in polycystic ovary syndrome? Fertil Steril. 65:1996;946-949.
20. Ehrmann D.A., Cavaghan M., Imperial J., Sturis J., Rosenfield R., Polonsky K.S. Effects of metformin on insuline secretion, insulina action and ovarian steroidogenesis in women with polycystic ovary syndrome. J Clin Endocrinol Metab. 82:1997;524-530.
21. Nestler J.E., Jakubowicz D.J. Decreases in ovarian cytochrome P450c17α activity and serum free testosterone after reduction of insulin secretion in polycystic ovary syndrome. N Engl J Med. 335:1996;617-623.